Neptune Assay Diluent is formulated to address nonspecific binding issues with human, porcine, or bovine serum or plasma samples tested in antigen-down ELISA formats. This non-mammalian assay additive works to enhance the specific anti-analyte/antigen antibody signal without denaturing the plate-adsorbed antigen molecules.
Neptune Assay Diluent is formulated to address nonspecific binding issues with human, porcine, or bovine serum samples. This non-mammalian assay additive works to enhance the specific anti-analyte/antigen antibody signal without denaturing the plate-adsorbed antigen molecules. This diluent is suitable for use with serum and plasma samples, and best for use in antigen-down ELISA formats. The Neptune Assay Diluent formulation includes non-mammalian protein and proprietary detergent additives to help minimize nonspecific background signal. This diluent also contains a proprietary calcium chelating agent designed to inhibit interference from complement and thrombin present in serum and plasma samples. Neptune Assay Diluent does not contain any immunoglobulin-based components that could interfere with anti-IgG signal-generating formats. An antimicrobial agent is included in the formulation to allow for bench-top use and storage stability. Bulk volumes and custom packaging are available upon request.
Domestic: Overnight Delivery; International: Priority Shipping
7.4 at 1X
Expires two years from date of manufacture
- Once the capture antigen has been coated onto the plate and the plate has been properly blocked with one of ICT’s stabilizing blocker products, pipette 50 – 100 µL of Neptune Assay Diluent into each of the wells of the ELISA plate using a multi-channel pipettor. The Assay Diluent is always added prior to adding the test and control serum/plasma samples to plate wells.
- The control and test samples should be diluted to the proper well concentrations using one of ICT’s three different Sample Diluent products. Using an ICT Sample Diluent to dilute the serum and plasma samples will also serve to help minimize the degree of nonspecific IgG binding to the antigen coated and blocked ELISA